HOME >> BIOLOGY >> NEWS
UCSF-led study offers insight into cancer development, resistance to therapy: finding focuses on Ras oncogene

UCSF-led scientists have determined that under certain conditions the Ras oncogene, a key culprit in many cancers, suppresses the function of the p53 tumor-suppressor gene, offering an important insight into the development of some cancers, and an explanation for why some cancers are resistant to radiation therapy. The finding is published in the current issue of Cell.

The Ras gene is part of a molecular pathway that transmits messages for cell growth - an essential component of cell function - from the surface of the cell into the cell's nucleus. But when mutated, as it is in a third of cancers, Ras functions like a gas pedal jammed to the floor, driving a cell into growth and replication overdrive. If coupled with enough other mutations causing destabilization of the cell's growth controls, the Ras oncogene can contribute to the development of cancer.

While Ras's direct role in many cancers has been known, the new finding suggests that, by regulating the p53 tumor-suppressor gene, Ras may play an indirect role in many more, says the co-lead author of the study, Stefan Ries, PhD, a postdoctoral fellow in the laboratory of senior author Frank McCormick, PhD, director of the UCSF Comprehensive Cancer Center.

"Ras's suppression of p53 could play an important role in inactivating the tumor suppressor during the early stages of some tumor development. This may be particularly true in colon cancers," says Ries.

The p53 tumor-suppressor gene is one of several genes that serve as a protector of a cell's DNA. If DNA has been damaged, as can occur during DNA replication and cell division or as a result of an environmental injury, the gene receives a signal that it should halt the cell's cycle of growth. If the cell repairs itself, p53 releases its brake; but if the damage remains, p53 induces cell death, which prevents the cell from continued growth and, ultimately, the dividing into daughter cells containing its damaged DNA. Mutations are a form of DNA damag
'"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
23-Oct-2000


Page: 1 2 3

Related biology news :

1. UCSF-led study raises doubts about marrow cell treatment for brain, heart
2. UCSF-led team reports new test improves detection of prions in animals
3. UCSF-led study points to pivotal, early event in cancer development
4. Student science contest participation influences study, career choices, alumni say
5. New study shows hope for treating inhalant abuse
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
8. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
11. Indiana University, EPA to study airborne PCBs

Post Your Comments:
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... Cranford, NJ (PRWEB) October 22, 2014 ... technologies and services – has been working with a ... Health and New Haven Farms Community Farming Collaborative to ... iPad-based ePRO solution. The study, which started in ... Wellness program that provides participants weekly exposure to and ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
Cached News: